The U.S. District Court for the Western District of Pennsylvania has entered a consent decree prohibiting Ranier’s Rx Laboratory Inc. from manufacturing or distributing compounded drugs until they comply with the Federal Food, Drug, and Cosmetic Act and Food and Drug Administration regulations, the FDA announced yesterday. A complaint filed with the consent decree alleges that the company’s purportedly sterile drug products were made under insanitary conditions. FDA last year alerted health care providers and patients not to use those products.

Related News Articles

Headline
The Food and Drug Administration Friday released draft guidance on how drug developers can apply for the agency’s Competitive Generic Therapies designation.
Headline
Members of the pharmaceutical distribution supply chain, including dispensers such as hospitals and pharmacies, can apply through March 11 to participate in a…
Headline
The Food and Drug Administration Friday warned physicians and patients who use medical devices to monitor levels of the blood thinner warfarin that certain…
Headline
The AHA today submitted to the Food and Drug Administration legislative, regulatory and best practice recommendations to address new and chronic prescription…
Headline
The Food and Drug Administration yesterday released revised draft guidance for facilities that compound human drugs as outsourcing facilities.
Headline
The AHA, American Society of Anesthesiologists, American Society of Clinical Oncology, American Society of Health-System Pharmacists, and Institute for Safe…